The shadow of generic challenges has long loomed over copyright’s blockbuster drug, Sildenafil, raising questions about the prospects of related medicinal ventures. While initial years saw substantial returns, the patent end has allowed the door for cheaper substitutes, likely reducing revenue and presenting a significant risk for investors pursu